ATE253912T1 - Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca - Google Patents

Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca

Info

Publication number
ATE253912T1
ATE253912T1 AT01927298T AT01927298T ATE253912T1 AT E253912 T1 ATE253912 T1 AT E253912T1 AT 01927298 T AT01927298 T AT 01927298T AT 01927298 T AT01927298 T AT 01927298T AT E253912 T1 ATE253912 T1 AT E253912T1
Authority
AT
Austria
Prior art keywords
medication
producing
treatment
receptor agonists
acetylcholine receptor
Prior art date
Application number
AT01927298T
Other languages
English (en)
Inventor
Benjamin R Yerxa
Ward M Peterson
Mathew Cowlen
Original Assignee
Inspire Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals filed Critical Inspire Pharmaceuticals
Application granted granted Critical
Publication of ATE253912T1 publication Critical patent/ATE253912T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01927298T 2000-04-21 2001-04-19 Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca ATE253912T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/557,059 US6277855B1 (en) 2000-04-21 2000-04-21 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
PCT/US2001/013034 WO2001080844A2 (en) 2000-04-21 2001-04-19 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
ATE253912T1 true ATE253912T1 (de) 2003-11-15

Family

ID=24223897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927298T ATE253912T1 (de) 2000-04-21 2001-04-19 Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca

Country Status (8)

Country Link
US (1) US6277855B1 (de)
EP (1) EP1214062B1 (de)
JP (1) JP2003531168A (de)
AR (1) AR028026A1 (de)
AT (1) ATE253912T1 (de)
AU (1) AU2001253765A1 (de)
DE (1) DE60101201D1 (de)
WO (1) WO2001080844A2 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US6455554B1 (en) * 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
CA2359813C (en) * 2000-10-24 2008-04-22 Richard L. Jones Nicotine mucosal spray
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7069084B2 (en) * 2002-06-14 2006-06-27 Seefit Incorporated Method and apparatus for preventing and treating eyelid problems
US7074812B2 (en) * 2002-08-02 2006-07-11 Nutraleutical Development Corporation Development of muscle mass in a mammal
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
MXPA05004121A (es) * 2002-10-18 2006-02-17 Molichem Medicines Inc Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
US7053064B2 (en) * 2002-11-08 2006-05-30 The Mclean Hospital Corporation Compounds for the treatment of tobacco dependence and withdrawal
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
RU2366428C2 (ru) * 2002-12-20 2009-09-10 Дзе Маклин Хоспитал Корпорейшн Соединения для нормализации цикла сна/бодрствования
US20060036220A1 (en) * 2003-01-22 2006-02-16 Kohji Kawahara Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye
US20050013806A1 (en) * 2003-04-04 2005-01-20 Chang Min S. Use of contact lens for corneal cell transplant
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
AU2003296968A1 (en) * 2003-12-12 2005-07-14 Richard W. Yee Method and apparatus for preventing and treating eyelid problems
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
US7326683B2 (en) * 2004-05-06 2008-02-05 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
CA2565545A1 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
PL1754491T3 (pl) * 2004-05-21 2010-08-31 Senju Pharma Co Preparat do oczu do wchłaniania przezskórnego zawierający agonistę receptora muskarynowego
WO2005118582A1 (ja) 2004-06-03 2005-12-15 Senju Pharmaceutical Co., Ltd. アミド化合物を含有する角膜知覚回復剤
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1765364A4 (de) * 2004-06-10 2010-09-22 Mclean Hospital Corp Pyrimidine, wie z:b: cytidin, bei der behandlung von patienten mit bipolaren störungen
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
EP1784199A4 (de) * 2004-08-11 2010-06-23 Mclean Hospital Corp Verbindungen zur behandlung von marihuana-abhängigkeit, entzug und konsum
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2007013661A1 (ja) * 2005-07-26 2007-02-01 Senju Pharmaceutical Co., Ltd. 眼科用経皮吸収型製剤
FR2889847B1 (fr) 2005-08-18 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
US8182840B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US20070237797A1 (en) * 2006-03-28 2007-10-11 Gholam A. Peyman Neural Conduit Agent Dissemination
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
JP4746714B2 (ja) * 2008-05-16 2011-08-10 Ａｘｉｓ株式会社 線維筋痛症治療用医薬組成物
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
JP2012505834A (ja) * 2008-10-14 2012-03-08 サイコジェニックス・インコーポレーテッド ニコチン性アセチルコリン受容体リガンドおよびその使用
EP2395974B1 (de) * 2009-02-11 2016-09-07 Heglund, a.s. Zusammensetzung für nikotinabsorption im mund zur rauchentwöhnung
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
RU2013127313A (ru) 2010-11-16 2014-12-27 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Системы и способы лечения сухого глаза
WO2012096866A2 (en) * 2011-01-10 2012-07-19 Inverseon, Inc. Use of beta-adrenergic inverse agonists for smoking cessation
ES2822301T3 (es) 2011-06-10 2021-04-30 Tissuetech Inc Métodos de procesamiento de tejidos de soporte fetal
CN103874762A (zh) 2011-08-26 2014-06-18 组织技术公司 胎儿支持组织的灭菌方法
US9132193B2 (en) 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
RU2510701C1 (ru) * 2012-12-19 2014-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения блефароконъюнктивальной формы синдрома сухого глаза
WO2014138709A1 (en) * 2013-03-08 2014-09-12 Oculeve, Inc. Devices and methods for treating dry eye in animals
EP2967817B1 (de) 2013-03-12 2021-03-10 Oculeve, Inc. Implantateinführungsvorrichtungen und -systeme
EP2986339A4 (de) 2013-04-19 2016-12-21 Oculeve Inc Nasenstimulationsvorrichtungen und -verfahren
US9770583B2 (en) 2014-02-25 2017-09-26 Oculeve, Inc. Polymer formulations for nasolacrimal stimulation
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
US9687652B2 (en) 2014-07-25 2017-06-27 Oculeve, Inc. Stimulation patterns for treating dry eye
SG10202011669PA (en) 2014-10-20 2020-12-30 Oyster Point Pharma Inc Methods of treating ocular conditions
EP3209371A4 (de) 2014-10-22 2018-10-24 Oculeve, Inc. Implantierbare nasenstimulatorsysteme und verfahren
EP3721938A1 (de) 2014-10-22 2020-10-14 Oculeve, Inc. Stimulationsvorrichtungen und -verfahren zur behandlung von trockenem auge
AU2015335772B2 (en) 2014-10-22 2020-07-09 Oculeve, Inc. Contact lens for increasing tear production
JP2017533917A (ja) * 2014-11-05 2017-11-16 ティッシュテック，インク． 神経成長および再生を促進するための組成物および方法
JP7030516B2 (ja) 2014-12-31 2022-03-07 マイクロオプティクス インコーポレイテッド 緑内障治療装置および方法
CA2985013C (fr) * 2015-05-21 2024-04-16 Ophtalmis Monaco Association d'acide lipoique et de taurine en tant qu'agent osmoprotecteur
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
AU2016331925B2 (en) 2015-09-30 2021-04-22 Microoptx Inc. Dry eye treatment devices and methods
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
CN109310692B (zh) * 2016-04-07 2022-01-25 奥伊斯特普安生物制药公司 治疗眼部病状的方法
US10639300B2 (en) 2016-04-12 2020-05-05 Arturo Solis Herrera Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
AU2017260237A1 (en) 2016-05-02 2018-11-22 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
EP3547898A4 (de) 2016-12-02 2020-07-08 Oculeve, Inc. Vorrichtung und verfahren zur vorhersage von trockenem auge und behandlungsempfehlung
TW202019424A (zh) * 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
WO2023279162A1 (en) * 2021-07-07 2023-01-12 University Of Canberra Methods of treatment and inhibition
DE102023208057A1 (de) 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868154A (en) 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
EP0659078B1 (de) 1992-08-31 2003-01-15 University Of Florida Research Foundation, Inc. Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DE19626373A1 (de) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Neuartige Verwendung von Wirkstoffen, welche die Funktion von nichtneuronalem Acetylcholin beeinflussen
US5830904A (en) 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Also Published As

Publication number Publication date
EP1214062A2 (de) 2002-06-19
EP1214062B1 (de) 2003-11-12
AU2001253765A1 (en) 2001-11-07
WO2001080844A2 (en) 2001-11-01
JP2003531168A (ja) 2003-10-21
AR028026A1 (es) 2003-04-23
US6277855B1 (en) 2001-08-21
WO2001080844A3 (en) 2002-03-28
DE60101201D1 (de) 2003-12-18

Similar Documents

Publication Publication Date Title
ATE253912T1 (de) Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca
ATE361058T1 (de) Tablette und verfahren zur herstellung derselben
DE60210409D1 (de) Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE60139256D1 (de) Verfahren und vorrichtung zur herstellung von flüssigen verabreichungsformen
EP1294410A4 (de) Verfahren und zusammensetzung zum reinigen von medizinischen geräten
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
CY2012032I2 (el) Ενωσεις 1,2-διυδροπυριδινης, διεργασια για την παρασκευη των ιδιων και χρηση εξ αυτων
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
DE60045394D1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
ATE388135T1 (de) Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen
DE69809284D1 (de) Immunomodulator mit anti-mikrobakteriellen und anti-mykobakteriellen eigenschaften, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen zur behandlung von mykobakteriosen sowie von chronischen und nicht-spezifischen lungenzuständen, sexuell übertragbaren krankheiten und den daraus resultierenden immunschwächen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
ATE290366T1 (de) Pharmazeutische formulierung mit überdecktem geschmack und verfahren zu ihrer herstellung
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE59912246D1 (de) Ferroelektrischer transistor und verfahren zu dessen herstellung
ATE313524T1 (de) 1,1- and 1,2-disubstituierte cyclopropane, verfahren zu deren herstellung und deren pharmazeutischen zusammensetzungen
DE50007390D1 (de) Doppel-gate-mosfet-transistor und verfahren zu seiner herstellung
DE50006026D1 (de) Wirkstoffhaltiges implantat-baustein-system und verfahren zu dessen herstellung
ATE250611T1 (de) Pyranoindole zur glaukombehandlung
ATE232723T1 (de) Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen
DE602005002776D1 (de) Verfahren zur Herstellung von 1,3-Dihydro-2H-3-Benzazepin-2-on und Anwendung zur Herstellung von Ivabradine und ihren pharmazeutischen annehmbaren Salzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties